Private Companies 13

UK

October 17, 2017: GE Healthcare Ltd. issued new U.S. patent [9,790,097]

NEWS BITES - PRIVATE COMPANIES

GE Healthcare Ltd. has been issued a new U.S. patent titled "Purification of.sup.68Ge/.sup.68Ga generator eluate from Fe(III) intended to improve specific radioactivity of.sup.68Ga-based radiopharmaceuticals" by the US Patent and Trademark Office.

ABSTRACT

The present invention provides a method of purifying.sup.68Ge/.sup.68Ga generator produced.sup.68Ga from Fe (III). The invention further relates to an automated system within an existing Gallea Synthia prototype that provides purification.sup.68Ga from various cations and preconcentrations of.sup.68Ga. In general, the present invention further depicts the use of an automated system for the production of.sup.68Ga-radiolabelled PET tracers with high specific radioactivity and a kit for purifying.sup.68Ge/.sup.68Ga generator produced.sup.68Ga from Fe (III).

Appl. No.15/274,503

INDEX

SECTION 1 GE HEALTHCARE LTD. PROFILE

SECTION 2 GE HEALTHCARE LTD. PATENTS

SECTION 1 GE HEALTHCARE LTD. PROFILE

1.1 ACTIVITIES

GE Healthcare Ltd. provides transformational medical technologies and services in the Americas, the Asia-Pacific, Europe, the Middle East, Africa, and India. It offers life care solutions, including anaesthesia drug delivery, diagnostic cardiology, perinatal care, and respiratory care and patient monitoring solutions; diagnostic imaging solutions, such as radiography, magnetic resonance imaging, and interventional image guided systems; intra-operative and interventional imaging products for minimally invasive surgical procedures; and ultrasound systems. The company also provides visualization, bone health, clinical consumable, computed tomography, contrast media, diagnostic cardiology, EP recording, metabolic health, healthcare IT, hemodynamic recording, home care, intensive care, life sciences, mammography, molecular imaging, patient monitoring, radiography and fluoroscopy, and surgical imaging products. In addition, it offers dose management and education solutions; and consulting and support services. The companys products are used in the areas of cardiology, neurology, emergency medicine, oncology, and womens health. GE Healthcare Ltd. was formerly known as GE Medical Systems. The company is headquartered in Chalfont St. Giles, United Kingdom. GE Healthcare Ltd. operates as a subsidiary of General Electric Company.

1.2 SUMMARY

Fiscal Year End: 31 Dec 2015

PermID: 5000001303

Website: http://www3.gehealthcare.co.uk

Industry: Healthcare Equipment/Supplies

SECTION 2 GE HEALTHCARE LTD. PATENTS

PREVIOUS 9 PATENT STORIES:

July 11, 2017 GE Healthcare Ltd. issued new U.S. patent [9,701,637]

ABSTRACT

An object of the present invention is to provide a probe for imaging a .beta.-sheet structure protein which can be used for the diagnosis of conformational diseases, particularly disease (tauopathy) having a cardinal symptom such as intracerebral accumulation of tau protein, for example, Alzheimer's disease. Another object of the present invention is to provide a compound which is highly specific to tau and can image tau with satisfactory sensitivity, and also has high brain transition, low or non-recognized bone-seeking properties and low or non-recognized toxicity. According to the present invention, the above problems are solved by providing a compound of a formula I (wherein A, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.a and R.sup.b are as defined in the present description) or a pharmaceutically acceptable salt or solvate thereof.

July 4, 2017 GE Healthcare Ltd. issued new U.S. patent [9,694,092]

ABSTRACT

The present invention relates to stabilised .sup.99mTc radiopharmaceutical compositions of the ligand tetrofosmin, which include an ascorbic acid or ascorbate radioprotectant, in the absence of an antimicrobial preservative. The invention also provides lyophilised kits suitable for the bulk preparation of multiple unit patient doses of .sup.99mTc-tetrofosmin metal complexes. Also disclosed are unit doses of .sup.99mTc-tetrofosmin, together with processes for preparing such unit doses from the lyophilised bulk vial.

January 3, 2017 GE Healthcare Ltd. issued new U.S. patent [9,533,059]

ABSTRACT

The present invention relates to imaging agent compositions comprising radiolabelled c-Met binding peptides suitable for positron emission tomography (PET) imaging in vivo. The c-Met binding peptides are labelled with the radioisotope .sup.18F. Also disclosed are pharmaceutical compositions, methods of preparation of the agents and compositions, plus methods of in vivo imaging using the compositions, especially for use in the management of cancer.

December 20, 2016 GE Healthcare Ltd. issued new U.S. patent [9,523,778]

ABSTRACT

The present invention relates to calibration and normalization systems and methods for ensuring the quality of radiopharmaceuticals during the synthesis thereof, such as radiopharmaceuticals used in Positron Emission Tomography (PET) and Single-Photon Emission Computed Tomography (SPECT).

November 15, 2016 GE Healthcare Ltd. issued new U.S. patent [9,493,504]

ABSTRACT

The present invention relates to the field of radiopharmaceuticals for in vivo imaging, in particular to a method of labelling a biological targeting molecule with a radioisotope. The method of the invention is particularly suitable for use with an automated synthesizer apparatus. Also provided are precursors in sterile form, as well as cassettes comprising such precursors useful in the method.

November 1, 2016 GE Healthcare Ltd. issued new U.S. patent [9,481,685]

ABSTRACT

The present invention concerns in vivo imaging and in particular in vivo imaging of the peripheral benzodiazepine receptor (PBR). A tetracyclic indole in vivo imaging agent is provided that binds with high affinity to PBR, has good uptake into the brain following administration, and which preferentially binds to tissues expressing higher levels of PBR. The present invention also provides a precursor compound useful in the synthesis of the in vivo imaging agent of the invention, as well as a method for synthesis of said in vivo imaging agent comprising use of said precursor compound, and a kit for carrying out said method. A cassette for the automated synthesis of the in vivo imaging agent is also provided. In addition, the invention provides a radiopharmaceutical composition comprising the in vivo imaging agent of the invention, as well as methods for the use of said in vivo imaging agent.

October 25, 2016 GE Healthcare Ltd. issued new U.S. patent [9,475,769]

ABSTRACT

The present invention relates to a method for the production of tricyclic indole compounds comprising a cyclization step wherein this step is improved over known methods.

October 18, 2016 GE Healthcare Ltd. issued new U.S. patent [9,468,694]

ABSTRACT

The invention relates to a process for preparation of a compound of formula (I): ##STR00001## R.sup.1 is selected from C.sub.1-6alkyl, C.sub.2-6alkenyl, and C.sub.2-6alkynyl; which comprises: (i) reaction with fluoride, suitably [.sup.18F]fluoride, of a corresponding compound of formula (II): ##STR00002## wherein R.sup.2 is selected from hydrogen, C.sub.1-10alkyl, C.sub.1-10haloalkyl, C.sub.6-14aryl, C.sub.6-14arylalkyl, --(CH.sub.2CH.sub.2O).sub.q--CH.sub.3 wherein q is an integer of from 1 to 10; R.sup.1 is as defined for the compound of formula (I); and R.sup.3 is a leaving group. Certain novel precursors of formula (II) and radiopharmaceutical kits containing such precursors are also claimed.

October 18, 2016 GE Healthcare Ltd. issued new U.S. patent [9,468,586]

ABSTRACT

A pierce and fill connector cap for a vial sealed by an elastomeric septum includes a vial collar and a needle holder. The vial collar body defines a collar aperture to be positioned in overlying registry with the septum of the vial, and the needle holder includes a needle holder body providing a means for holding a pair of elongate needles in registry with the collar aperture. The needle holder body holds at least one needle therein in a bent or deflected orientation and is moveable with respect to the vial collar between a first position spaced from the vial collar and a second position proximate the vial collar, such that the needled held by the needle holder will puncture through the vial septum.

PermID: 5000001303

Created by www.buysellsignals.com for News Bites Finance